Other
Nab-Paclitaxel
0
Pipeline Programs↗
10
Active Trials↗
6
Companies Involved↗
Nab-paclitaxel is an early-stage landscape with 0 programs across 6 companies. The most active players are Novartis, Pfizer, Bristol-Myers Squibb.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
35
clinical trials
Completed14 · 40%
Unknown status7 · 20%
Recruiting7 · 20%
Terminated4 · 11%
Not yet recruiting3 · 9%
Clinical Trials
Trial Activity
35 trials
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06632405·60 enrolled
Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC
Not yet recruiting·—·Phase 2·NCT07103447·54 enrolled
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Completed·—·Phase 2·NCT02716038·39 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)